Document is current
Any future updates will be listed below
-
Authors
Hamazaki, Nobuhiko http://orcid.org/0000-0001-9228-233X
Yang, Wei
Kubo, Connor A. http://orcid.org/0000-0001-9579-2917
Qiu, Chengxiang http://orcid.org/0000-0002-6346-8669
Martin, Beth K. http://orcid.org/0000-0002-9661-014X
Garge, Riddhiman K.
Regalado, Samuel G.
Nichols, Eva K.
Pendyala, Sriram
Bradley, Nicholas
Fowler, Douglas M. http://orcid.org/0000-0001-7614-1713
Lee, Choli http://orcid.org/0000-0002-8901-1835
Daza, Riza M. http://orcid.org/0000-0003-1635-8675
Srivatsan, Sanjay
Shendure, Jay http://orcid.org/0000-0002-1516-1865
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (UM1HG011586)
Howard Hughes Medical Institute
Paul G. Allen Frontiers Group
- License Information
-
More Information
Article History
Received: 5 February 2024
Accepted: 17 July 2024
First Online: 20 August 2024
Competing interests
: J.S. is a scientific advisory board member, consultant and/or co-founder of Prime Medicine, Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Sixth Street Capital, Pacific Biosciences and Somite Therapeutics. The other authors declare no competing interests.
